TriangleAR Blockade (NCT05534646)
AR Blockade trial for Castration-resistant Prostate Cancer (NCT05534646). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic castration-resistant prostate cancer and rising PSA after one or two androgen-signaling inhibitors, who decline or cannot receive taxanes.
The idea: add carotuximab, which targets CD105 to inhibit tumor blood-vessel growth, to androgen-receptor blockade. Enzalutamide-naive patients compare enzalutamide alone against the combination; previously exposed patients receive the combination. A safety group uses apalutamide instead. Monotherapy patients can cross over after progression. Researchers measure progression-free survival and toxicity. Prior-treatment restrictions apply.
This phase 2 study plans 116 patients. Edwin Posadas leads three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.